UNSPSC 51422418: Tixocortol

This classification denotes a hydrocortisone analog and 21-thiol hydrocortisone derivative with the molecular formula C21H30O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZX3KEK657Z, chemically known as 11beta,17-dihydroxy-21-mercapto-4-pregnen-3,20-dion but generally known as tixocortol, which bears US NIH Compound Identifier 162955. European Medicines Agency schedules Tixocortol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11127MIG.

UNSPSC 51422418 Tixocortol, a Commodity code, nominally covers individual pharmaceutical products, but the recent state and local opportunities posted under this code do not involve tixocortol procurement itself. Instead, the code tags solicitations for naloxone, drug deactivation systems, and direct-to-manufacturer prescription program management—pharmaceutical supply chains and opioid-response services rather than a single active pharmaceutical ingredient. State and local issuing bodies under this code span county health departments and state health and human services agencies. Seminole County, Florida, which represents the most concrete recent opportunity, is purchasing operational pharmaceutical inventory (naloxone and safe drug deactivation systems) as part of community health and overdose-response initiatives rather than clinical or research-grade chemical compounds. The work involves vendor selection for recurring supply of finished pharmaceutical goods with quarterly delivery, compliance with E-Verify and drug-free workplace certification, and insurance maintenance.

Activity under this code is concentrated in Florida and Texas based on recent postings. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response date April 3, 2026) to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct contracting pathways between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI is exploratory and does not commit to specific contract values or timelines but signals intent to move toward formal procurement after market intelligence gathering.